Patent details
93015
Product Name:
"Carfilzomib eventuellement sous forme d'un sel pharmaceutiquement acceptable"
Basic Information
- Publication number:
- 93015
- Type:
- SPC
- SPC Type:
- Medical
- Basic Patent Number:
-
EP057844847
- Legal Status:
- Inactive
- Application number:
- 93015
- First applicant's nationality:
- Procedural language:
- French
Marketing Authorization
- Marketing Authorization Number:
- EU/1/15/1060 - Kyprolis -carfilzomib
- Marketing Authorization Type:
-
- Marketing Authorization Date:
- 23/11/2015
- Marketing Authorization Status:
- Accepted
- Marketing Authorization Country:
-
Dates
- Filing date:
- 06/04/2016
- First Marketing Authorization date:
- 23/11/2015
- Grant date:
- 06/06/2016
- Activation date:
- Publication date:
- 06/06/2016
- Lapsed date:
- Expiration date:
- Renunciation date:
- Revocation date:
- Annulment date:
- Basic SPC Expiration:
- 08/08/2030
- SPC Extension Expiration:
- 08/08/2030
- Rejection date:
- Withdrawal date:
Owner
- From:
- 20/04/2016
-
-
- Name:
- ONYX THERAPEUTICS, INC.
- Address:
- 249 E. GRAND AVENUE, SOUTH SAN FRANCISCO, CA 94080, United States (US)
History of Owners
- From:
- 06/04/2016
- To:
- 19/04/2016
- Name:
- Onyx Therapeutics Inc.
- Address:
- c/o Onyx Pharmaceuticals, Inc. 2100 Powell Street, Emeryville, CA 94608, United States (US)
Agent
- Name:
- OFFICE FREYLINGER S.A.
- From:
- 06/04/2016
- Address:
- Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)
- To:
Inventor
1
- Name:
- LAIDIG Guy, J.
- Address:
- United States (US)
2
- Name:
- SMYTH Mark, S.
- Address:
- United States (US)
Annual Fees
- Annual Fee Due Date:
- 31/08/2025
- Annual Fee Number:
- 21
- Annual Fee Amount:
- 410 Euro
- Expected Payer:
-
- Last Annual Fee Payment Date:
-
- Last Annual Fee Paid Number:
-
- Payer:
-
Filing date |
Document type |
Number of pages |